Cargando…

Tumour targeting of humanised cross-linked divalent-fab′ antibody fragments: a clinical phase I/II study

Antibody engineering has made it possible to design antibodies with optimal characteristics for delivery of radionuclides for tumour imaging and therapy. A humanised divalent-Fab′ cross-linked with a bis-maleimide linker referred to as humanised divalent-Fab′ maleimide was produced as a result of th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Casey, J L, Napier, M P, King, D J, Pedley, R B, Chaplin, L C, Weir, N, Skelton, L, Green, A J, Hope-Stone, L D, Yarranton, G T, Begent, R H J
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2002
Materias:	Clinical
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375360/ https://www.ncbi.nlm.nih.gov/pubmed/11986771 http://dx.doi.org/10.1038/sj.bjc.6600198

Ejemplares similares

Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.
por: Casey, J. L., et al.
Publicado: (1996)

Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab́ fragments
por: Casey, J L, et al.
Publicado: (1999)

Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification.
por: Delgado, C., et al.
Publicado: (1996)

Clearance of yttrium-90-labelled anti-tumour antibodies with antibodies raised against the 12N4 DOTA macrocycle.
por: Casey, J. L., et al.
Publicado: (1998)

Single chain Fab (scFab) fragment
por: Hust, Michael, et al.
Publicado: (2007)

Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab')2 fragments of an anti-tumour antibody.
por: Marshall, D., et al.
Publicado: (1995)

Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM).
por: Antoniw, P., et al.
Publicado: (1996)

Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy.
por: King, D. J., et al.
Publicado: (1995)

Fractionated (131)I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice
por: Violet, J A, et al.
Publicado: (2008)

Production of single chain Fab (scFab) fragments in Bacillus megaterium
por: Jordan, Eva, et al.
Publicado: (2007)

Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model.
por: Pedley, R. B., et al.
Publicado: (1993)

Humanising the mouse genome piece by piece
por: Zhu, Fei, et al.
Publicado: (2019)

Cytochrome P450 humanised mice
por: Gonzalez, Frank J
Publicado: (2004)

DutaFabs are engineered therapeutic Fab fragments that can bind two targets simultaneously
por: Beckmann, Roland, et al.
Publicado: (2021)

Production of Antibody Fab Fragments in Escherichia coli
por: Tachibana, Hiroshi, et al.
Publicado: (2011)

Crystal structures and molecular dynamics simulations of a humanised antibody fragment at acidic to basic pH
por: Tang, Jiazhi, et al.
Publicado: (2023)

Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies.
por: Lane, D. M., et al.
Publicado: (1994)

Engineering the Fab fragment of the anti-IgE omalizumab to prevent Fab crystallization and permit IgE-Fc complex crystallization
por: Mitropoulou, Alkistis N., et al.
Publicado: (2020)

Use of digoxin-specific antibody fragments (Fab) in the management of digoxin poisoning.
por: Brown, J. H., et al.
Publicado: (1986)

The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody.
por: Pedley, R. B., et al.
Publicado: (1994)

In vitro and in vivo anticancer efficacy of unconjugated humanised anti-CEA monoclonal antibodies
por: Blumenthal, R D, et al.
Publicado: (2008)

Bicistronic DNA display for in vitro selection of Fab fragments
por: Sumida, Takeshi, et al.
Publicado: (2009)

Characterization of a recombinant humanized anti-cocaine monoclonal antibody and its Fab fragment
por: Kirley, Terence L, et al.
Publicado: (2015)

Reply: In vitro and in vivo anticancer efficacy of unconjugated humanised anti-CEA monoclonal antibodies
por: Ashraf, S Q, et al.
Publicado: (2008)

Data on crystal organization in the structure of the Fab fragment from the NIST reference antibody, RM 8671
por: Gallagher, D.T., et al.
Publicado: (2017)

The qualitative method for a humanisation of research
por: Artioli, Giovanna, et al.
Publicado: (2021)

Characterisation and internalisation of recombinant humanised HMFG-1 antibodies against MUC1
por: Pericleous, L M, et al.
Publicado: (2005)

Tumour imaging by the detection of fibrin clots in tumour stroma using an anti-fibrin Fab fragment
por: Obonai, Toshifumi, et al.
Publicado: (2016)

Fragments of the Fab-3 and Fab-4 Boundaries of the Drosophila melanogaster Bithorax Complex That Include CTCF Sites Are not Effective Insulators
por: Kyrchanova, O. V., et al.
Publicado: (2022)

Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody.
por: Marshall, D., et al.
Publicado: (1996)

Centering and humanising health systems: empowerment through Kangaroo Mother Care
por: Willson, Marisa, et al.
Publicado: (2021)

Uses for humanised mouse models in precision medicine for neurodegenerative disease
por: Nair, Remya R., et al.
Publicado: (2019)

Anti-colchicine Fab fragments prevent lethal colchicine toxicity in a porcine model: a pharmacokinetic and clinical study
por: Eddleston, Michael, et al.
Publicado: (2018)

Reactive Heterobimetallic Complex Combining Divalent Ytterbium and Dimethyl Nickel Fragments
por: Wang, Ding, et al.
Publicado: (2019)

Humanising and dehumanising pigs in genomic and transplantation research
por: Lowe, James W. E.
Publicado: (2022)

Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model.
por: Marshall, D., et al.
Publicado: (1994)

HIV-2 neutralization by intact V3-specific Fab fragments
por: Sourial, Samer, et al.
Publicado: (2008)

Modification of Fab Fragments by Dibromopyridazinediones Carrying Mono- and Double-Biotin Functionalities
por: Matsushita, Takahiko, et al.
Publicado: (2022)

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours
por: Attard, G, et al.
Publicado: (2007)

Improved Characteristics of RANKL Immuno-PET Imaging Using Radiolabeled Antibody Fab Fragments
por: Dewulf, Jonatan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6h9mtt3rhi235mj7ngldivqff8